WVE vs. KRYS, CYTK, RYTM, PTCT, SRPT, RNA, SWTX, RARE, AKRO, and ACLX
Should you be buying Wave Life Sciences stock or one of its competitors? The main competitors of Wave Life Sciences include Krystal Biotech (KRYS), Cytokinetics (CYTK), Rhythm Pharmaceuticals (RYTM), PTC Therapeutics (PTCT), Sarepta Therapeutics (SRPT), Avidity Biosciences (RNA), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Akero Therapeutics (AKRO), and Arcellx (ACLX). These companies are all part of the "pharmaceutical products" industry.
Wave Life Sciences vs.
Krystal Biotech (NASDAQ:KRYS) and Wave Life Sciences (NASDAQ:WVE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, community ranking, risk, media sentiment, profitability and institutional ownership.
Krystal Biotech presently has a consensus price target of $211.13, suggesting a potential upside of 68.51%. Wave Life Sciences has a consensus price target of $21.17, suggesting a potential upside of 247.56%. Given Wave Life Sciences' higher probable upside, analysts plainly believe Wave Life Sciences is more favorable than Krystal Biotech.
86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 89.7% of Wave Life Sciences shares are held by institutional investors. 13.7% of Krystal Biotech shares are held by insiders. Comparatively, 29.1% of Wave Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Krystal Biotech has a net margin of 30.69% compared to Wave Life Sciences' net margin of -66.50%. Krystal Biotech's return on equity of 11.41% beat Wave Life Sciences' return on equity.
Wave Life Sciences received 69 more outperform votes than Krystal Biotech when rated by MarketBeat users. However, 67.80% of users gave Krystal Biotech an outperform vote while only 67.77% of users gave Wave Life Sciences an outperform vote.
In the previous week, Wave Life Sciences had 1 more articles in the media than Krystal Biotech. MarketBeat recorded 11 mentions for Wave Life Sciences and 10 mentions for Krystal Biotech. Wave Life Sciences' average media sentiment score of 1.30 beat Krystal Biotech's score of 1.20 indicating that Wave Life Sciences is being referred to more favorably in the news media.
Krystal Biotech has higher revenue and earnings than Wave Life Sciences. Wave Life Sciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
Krystal Biotech has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Wave Life Sciences has a beta of -0.92, indicating that its share price is 192% less volatile than the S&P 500.
Summary
Krystal Biotech beats Wave Life Sciences on 10 of the 17 factors compared between the two stocks.
Get Wave Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for WVE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Wave Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:WVE) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy WVE Stock Free WVE Stock Alerts